Additional Reimbursement Considerations in Oncology

During this discussion, Scott Gottlieb, MD; Michael Kolodziej, MD; and Ted Okon, MBA, further discuss how various reimbursement models are impacting clinical practice in oncology.

Dr Gottlieb begins by explaining why the CMS stepped in to regulate the practice of medicine by implementing additional rules regarding the provision of oncology products.

Healthcare reform has impacted oncology care in the United States in many ways, including the establishment of oncology medical homes and the implementation of payment reform models, remarks Mr Okon. He also describes differences in drug pricing in the community setting versus the hospital setting, and discusses the so-called drug incentive.

When establishing measures to help improve current healthcare models, various stakeholders should collaborate and discuss opportunities for achieving optimal efficiency, suggests Mr Okon. Stakeholders also need to work together to improve the reimbursement model for oncology services.